Skip to main content

RECOMBITEK C3

This page contains information on RECOMBITEK C3 for veterinary use.
The information provided typically includes the following:
  • RECOMBITEK C3 Indications
  • Warnings and cautions for RECOMBITEK C3
  • Direction and dosage information for RECOMBITEK C3

RECOMBITEK C3

This treatment applies to the following species:
Company: Boehringer Ingelheim Animal Health

rDAP SWD

Dogs

1 mL

Canine Distemper-Adenovirus Type 2-Parvovirus Vaccine

Modified Live Virus, Canarypox Vector

RECOMBITEK C3 Indications

This product has been shown to be effective for the vaccination of healthy dogs 6 weeks of age and older against canine distemper virus, canine adenovirus type 1 (canine hepatitis), canine adenovirus type 2 (canine respiratory disease complex), and canine parvovirus. The duration of immunity has not been determined. For more information regarding efficacy and safety data, see productdata.aphis.usda.gov.

Description

Recombitek® C3 contains a lyophilized suspension of a recombinant canarypox vector expressing the HA and F glycoproteins of canine distemper virus; modified live adenovirus type 2, and parvovirus; plus sterile water diluent. Safety and immunogenicity of this product have been demonstrated by vaccination and challenge tests in susceptible dogs.

Directions and dosage: Aseptically rehydrate the lyophilized vaccine with the accompanying liquid diluent, and agitate. Administer 1 mL (1 dose) subcutaneously or intramuscularly into healthy dogs.

For primary vaccination, revaccinate with a second 1 mL dose 2 to 3 weeks later. The presence of maternal antibody is known to interfere with the development of active immunity in dogs and additional boosters will be required in most young animals. For advice on revaccination frequency, consult your veterinarian.

Precautions

Use entire contents immediately after reconstitution. Contains gentamicin as a preservative. In rare instances, administration of vaccines may cause lethargy, fever, and inflammatory or hypersensitivity types of reactions. Transient lethargy, as well as pain and swelling at the site of injection, may occur following use of this product. Treatment may include antihistamines, anti-inflammatories, and/or epinephrine, as directed by a veterinarian. This product has not been tested in pregnant animals. In case of human exposure, contact a physician. Inactivate unused contents before disposal.

Store at 2-8°C (35-46°F). Do not use chemicals to sterilize syringes and needles. Do not mix with other products, except as specified on the label.

For use in animals only. Sold to veterinarians only.

Recombitek® is a registered trademark in the USA of Boehringer Ingelheim Animal Health USA Inc.

Recombitek® is a registered trademark in Canada of Boehringer Ingelheim Vetmedica GmbH. Used under license.

Manufactured by:

Boehringer Ingelheim Animal Health USA Inc., Athens, GA 30601 USA

Phone: 1 (888) 637-4251

VLN/PCN 124/1331.R1

Distributed in Canada by:

Boehringer Ingelheim Animal Health Canada Inc., Burlington ON L7L 5H4

Contains:

Prod. No.

 

25 doses

25 x 1 dose, Lyophilized

25 x 1 mL, Sterile Diluent

2263-25

RM2003R6

CPN: 1028365.0

BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
3239 SATELLITE BLVD., BLDG 500, DULUTH, GA, 30096
Telephone:   800-325-9167
Customer Service:   888-637-4251
Technical Service:   888-637-4251
Fax:   816-236-2717
Website:   www.boehringer-ingelheim.com
THIS SERVICE AND DATA ARE PROVIDED "AS IS". DVMetrics assumes no liability, and each user assumes full risk, responsibility, and liability, related to its use of the DVMetrics service and data. See the Terms of Use for further details.

Copyright © 2024 Animalytix LLC. Updated: 2024-02-27